Positive News SentimentPositive NewsNASDAQ:EMBC Embecta (EMBC) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free EMBC Stock Alerts $12.37 -0.06 (-0.48%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$12.27▼$13.0450-Day Range$10.13▼$14.6052-Week Range$9.93▼$28.36Volume994,576 shsAverage Volume484,304 shsMarket Capitalization$713.38 millionP/E Ratio10.22Dividend Yield4.85%Price Target$13.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Embecta alerts: Email Address Embecta MarketRank™ Stock AnalysisAnalyst RatingReduce1.50 Rating ScoreUpside/Downside5.1% Upside$13.00 Price TargetShort InterestBearish5.15% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth2.17%From $2.30 to $2.35 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.10 out of 5 starsMedical Sector802nd out of 928 stocksSurgical & Medical Instruments Industry90th out of 100 stocks 0.8 Analyst's Opinion Consensus RatingEmbecta has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageEmbecta has only been the subject of 1 research reports in the past 90 days.Read more about Embecta's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.15% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Embecta has recently increased by 4.51%, indicating that investor sentiment is decreasing. Previous Next 3.3 Dividend Strength Dividend LeadershipEmbecta is a leading dividend payer. It pays a dividend yield of 4.85%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthEmbecta has only been increasing its dividend for 1 years.Dividend CoverageThe dividend payout ratio of Embecta is 49.59%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Embecta will have a dividend payout ratio of 25.53% next year. This indicates that Embecta will be able to sustain or increase its dividend.Read more about Embecta's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EMBC. Previous Next 3.3 News and Social Media Coverage News SentimentEmbecta has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Embecta this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for EMBC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Embecta to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Embecta insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.28% of the stock of Embecta is held by insiders.Percentage Held by Institutions93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Embecta's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Embecta are expected to grow by 2.17% in the coming year, from $2.30 to $2.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Embecta is 10.22, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 122.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Embecta is 10.22, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.77.Read more about Embecta's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe Worst is Yet to Come…Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly.Click here to stream this controversial exposé now. About Embecta Stock (NASDAQ:EMBC)Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Read More EMBC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EMBC Stock News HeadlinesMay 21, 2024 | investorplace.comTrade Winds Turning: 3 Stocks Poised to Gain from Biden's China TariffsMay 13, 2024 | finance.yahoo.comEmbecta Corp. (NASDAQ:EMBC) Q2 2024 Earnings Call TranscriptMay 13, 2024 | seekingalpha.comEmbecta Corp. (EMBC) Q2 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comEmbecta Corp (EMBC) Surpasses Analyst Revenue Forecasts in Q2 Fiscal 2024May 10, 2024 | finance.yahoo.comEmbecta Second Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | marketwatch.comEmbecta Shares Rise After 2Q Results, Higher FY GuidanceMay 9, 2024 | globenewswire.comEmbecta Corp. Reports Second Quarter Fiscal 2024 Financial ResultsMay 9, 2024 | globenewswire.comembecta Announces Quarterly Cash DividendMay 8, 2024 | markets.businessinsider.comEmbecta earnings preview: what Wall Street is expectingMay 4, 2024 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Embecta StockMay 1, 2024 | globenewswire.comembecta to Participate in Investor EventsApril 23, 2024 | globenewswire.comembecta to Report Fiscal Second Quarter 2024 Financial ResultsApril 16, 2024 | finance.yahoo.comEmbecta Corp. (EMBC) Stock Historical Prices & Data - Yahoo FinanceMarch 11, 2024 | finance.yahoo.comEMBC Apr 2024 10.000 putMarch 11, 2024 | finance.yahoo.comEMBC Apr 2024 20.000 callMarch 6, 2024 | globenewswire.comembecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 DiabetesFebruary 13, 2024 | finance.yahoo.comEmbecta (NASDAQ:EMBC) Has Affirmed Its Dividend Of $0.15February 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: McKesson (MCK), Embecta Corporation (EMBC) and Abbott Labs (ABT)February 10, 2024 | markets.businessinsider.comEmbecta Shareholders Approve Directors and Compensation PlansFebruary 10, 2024 | insidermonkey.comEmbecta Corp. (NASDAQ:EMBC) Q1 2024 Earnings Call TranscriptFebruary 9, 2024 | marketwatch.comEmbecta Shares Fall Despite Outlook Raise, Strong 1QFebruary 9, 2024 | markets.businessinsider.comEmbecta Sinks As Outlook Comes In Below ConsensusFebruary 9, 2024 | finance.yahoo.comWhy Embecta Stock Is Tanking TodayFebruary 9, 2024 | fool.comWhy Embecta Stock Is Tanking TodayFebruary 9, 2024 | msn.comEmbecta beats top-line and bottom-line estimates; updates FY24 outlookSee More Headlines Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 3/15 Dividend2/27/2024Dividend Payable3/15/2024Last Earnings5/09/2024Ex-Dividend for 6/14 Dividend5/24/2024Today6/02/2024Dividend Payable6/14/2024Next Earnings (Estimated)8/13/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:EMBC CUSIPN/A CIK1872789 Webwww.embecta.com Phone201-847-6880FaxN/AEmployees2,200Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$13.00 Low Stock Price Target$13.00 Potential Upside/Downside+5.1%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$1.21 Trailing P/E Ratio10.22 Forward P/E Ratio5.38 P/E GrowthN/ANet Income$70.40 million Net Margins6.20% Pretax Margin4.35% Return on Equity-18.42% Return on Assets12.05% Debt Debt-to-Equity RatioN/A Current Ratio2.29 Quick Ratio1.79 Sales & Book Value Annual Sales$1.12 billion Price / Sales0.64 Cash Flow$3.67 per share Price / Cash Flow3.37 Book Value($13.35) per share Price / Book-0.93Miscellaneous Outstanding Shares57,670,000Free Float57,509,000Market Cap$713.38 million OptionableOptionable Beta0.86 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Devdatt Kurdikar (Age 56)President, CEO & Director Comp: $2.2MMr. Jacob P. Elguicze (Age 51)Senior VP & CFO Comp: $1.05MMr. Brian R. Capone (Age 49)VP, Chief Accounting Officer & Corporate Controller Comp: $645.16kMr. Jeffrey Z. Mann (Age 52)Senior VP, General Counsel, Head of Business Development & Corporate Secretary Comp: $959.45kMr. Shaun Curtis (Age 55)Senior Vice President of Global Manufacturing & Supply Chain Comp: $915.67kMs. Colleen Riley (Age 60)Senior VP & Chief Technology Officer Mr. Pravesh KhandelwalVP & Head of Investor RelationsMs. Ginny BlockiSenior Vice President of Global Marketing & Product ManagementMs. Jean M. Casner (Age 66)Senior VP & Chief Human Resources Officer Mr. Tom Blount (Age 50)Senior VP & President of North America More ExecutivesKey CompetitorsiRhythm TechnologiesNASDAQ:IRTCICU MedicalNASDAQ:ICUIIntegra LifeSciencesNASDAQ:IARTNovoCureNASDAQ:NVCRUFP TechnologiesNASDAQ:UFPTView All CompetitorsInsiders & InstitutionsComerica BankSold 63,990 shares on 5/17/2024Ownership: 0.043%Janus Henderson Group PLCSold 626,784 shares on 5/16/2024Ownership: 1.941%Jacobs Levy Equity Management Inc.Bought 313,951 shares on 5/16/2024Ownership: 1.115%California State Teachers Retirement SystemSold 2,963 shares on 5/16/2024Ownership: 0.100%Bayesian Capital Management LPBought 1,500 shares on 5/16/2024Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions EMBC Stock Analysis - Frequently Asked Questions Should I buy or sell Embecta stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Embecta in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" EMBC shares. View EMBC analyst ratings or view top-rated stocks. What is Embecta's stock price target for 2024? 2 brokerages have issued 1-year target prices for Embecta's stock. Their EMBC share price targets range from $13.00 to $13.00. On average, they anticipate the company's share price to reach $13.00 in the next year. This suggests a possible upside of 5.1% from the stock's current price. View analysts price targets for EMBC or view top-rated stocks among Wall Street analysts. How have EMBC shares performed in 2024? Embecta's stock was trading at $18.93 at the beginning of 2024. Since then, EMBC stock has decreased by 34.7% and is now trading at $12.37. View the best growth stocks for 2024 here. When is Embecta's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our EMBC earnings forecast. How were Embecta's earnings last quarter? Embecta Corp. (NASDAQ:EMBC) announced its earnings results on Thursday, May, 9th. The company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.43 by $0.24. The company earned $287.20 million during the quarter, compared to the consensus estimate of $264.70 million. Embecta had a negative trailing twelve-month return on equity of 18.42% and a net margin of 6.20%. The firm's quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.75 EPS. How often does Embecta pay dividends? What is the dividend yield for Embecta? Embecta announced a quarterly dividend on Thursday, May 9th. Investors of record on Tuesday, May 28th will be paid a dividend of $0.15 per share on Friday, June 14th. This represents a $0.60 dividend on an annualized basis and a yield of 4.85%. The ex-dividend date is Friday, May 24th. Read our dividend analysis for EMBC. Is Embecta a good dividend stock? Embecta (NASDAQ:EMBC) pays an annual dividend of $0.60 per share and currently has a dividend yield of 4.85%. EMBC has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 49.59%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, EMBC will have a dividend payout ratio of 25.53% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for EMBC. What ETFs hold Embecta's stock? ETFs with the largest weight of Embecta (NASDAQ:EMBC) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE) and Syntax Stratified SmallCap ETF (SSLY).Invesco S&P Spin-Off ETF (CSD). What guidance has Embecta issued on next quarter's earnings? Embecta updated its FY 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share (EPS) guidance of 2.200-2.300 for the period, compared to the consensus estimate of 2.100. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Who are Embecta's major shareholders? Embecta's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (12.53%), Janus Henderson Group PLC (1.94%), Jacobs Levy Equity Management Inc. (1.12%), First Eagle Investment Management LLC (0.72%), Sei Investments Co. (0.63%) and Principal Financial Group Inc. (0.52%). Insiders that own company stock include David F Melcher, Devdatt Kurdikar, Jacob Elguicze and Jeffrey Z Mann. View institutional ownership trends. How do I buy shares of Embecta? Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EMBC) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
